Canadian International Pharma Corp. Enters Into Letter of Intent with Nikma Darou Chimie

News Release No: 16-04

Trading symbols: TSX-V - NEX: CIP.H

Frankfurt: BP4

Canadian International Pharma Corp. Enters Into Letter of Intent with Nikma Darou Chimie

West Vancouver, British Columbia, February 10, 2016 – Canadian International Pharma Corp. (the “Company” or “CIPC”) – CIPC is pleased to announce that it has entered into a letter of intent (the “Letter of Intent”) with Nikma Darou Chimie (“Nikma”) an Iranian company, setting out the general terms and conditions for a proposed licensing agreement for 99 generic medications. The Letter of Intent will form the basis of a comprehensive licensing agreement (the “Licensing Agreement”), and will be subject to regulatory approval.

The proposed transaction will grant CIPC the rights to manufacture, or have manufactured, market and sell 99 generic medications formulated by Nikma. The list of available medications include formulations and process for anti-inflammatory and pain killers, cholesterol lowering agents, anti-anxiety, asthma, antibiotics, cardiovascular medicines, ulcer and reflux and others, including multiple supplements and vitamins. As part of the proposed transaction, CIPC will issue 1,000,000 shares to Nikma in exchange for use of the formulations and process for each of the generic medications. Additionally, a licencing royalty is payable by CIPC to Nikma based on sales of medications made based on the formulations.

“This proposed licensing agreement promises to save CIPC valuable time in research and development, and enormous expense, in introducing medications to international markets. By combining Nikma’s more than 20 years expertise in developing generic formulations, and CIPC’s ability to market and sell the medications in various markets, we view this as a winning partnership,” said Douglas L. Mason, CEO and Chairman of Canadian International Pharma Corp.

About Nikma Darou Chimie

Nikma Daru Chemie (“Nikma”) is a privately held company that is operating in the pharmaceutical industry in Iran. Since inception in 2007, Nikma has been active in research and development of generic medication, developing formulations and Common Technical Documents (“CTD’s”), licensing formulations to manufacturers and importing active pharmaceutical ingredients and finished products for local manufacturers. Nikma has been active in multiple categories of pharmaceutical products such as cardiovascular and antihyperlipidemic agents, NSAID’s and analgesics, central nervous system and anti anxiety agents, antidiabetics, antihistamines, gastrointestinal, antibiotics, as well as multiple nutritional supplements and vitamins.

Nikma is a registered company in Iran, which has permissions to import and export, develop CTD’s, produce and package, and to perform all laboratory work on all pharmaceutical products in all forms.

About Canadian International Pharma Corp.

Canadian International Pharma Corp (“CIPC” or the “Company”) intends to develop a multi-faceted generic drug manufacturing, distribution and testing / certification company. Once CIPC has obtained its expected Canadian Good Manufacturing (“GMP”) license, it intends The Company also plans to utilize its anticipated GMP license and its planned Canadian manufacturing facility to produce generics and neutraceuticals in Canada for the Canadian market. CIPC is also focussed on applying GMP standards to generics manufactured outside of Canada so that these generics can be certified and tested on an ongoing basis as meeting Canadian standards. CIPC also plans to take advantage of international market demands for Canadian and US manufactured neutraceuticals through the Company’s network of sales agents in China, the Middle East, UAE and Eastern Europe. In connection therewith, CIPC intends to negotiate and establish distribution agreements with Canadian and US neutraceuticals manufacturers.

For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company’s website at www.canpharmacorp.ca.

CANADIAN INTERNATIONAL PHARMA CORP.

“Douglas L. Mason”

____________________________________________ Douglas L. Mason, Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this release.

FORWARD LOOKING STATEMENTS

This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable securities legislation. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”, ”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in, or implied by, this forward looking information. Factors that could cause actual results to differ materially from those in forward-looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals required for the Company’s business plans, continued availability of capital and financing, and general economic, market or business conditions. Any forward-looking statements are expressly qualified in their entirety by this cautionary statement. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.